OpenLobby.EU
Explore

AstraZeneca PLC

AstraZeneca is a global science-led biopharmaceutical company specializing in oncology and respiratory treatments.

Lobbying Activity

Meeting with Ulla Schwager (Head of Unit Competition) and Johnson Johnson and

3 Dec 2025 · Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector

Meeting with Saila Rinne (Head of Unit Communications Networks, Content and Technology)

18 Nov 2025 · AI in health.

Meeting with Victor Negrescu (Member of the European Parliament) and Merck Sharp Dohme Europe Belgium SRL and

4 Nov 2025 · EUROPA CONNECT - Health EU Summit

Meeting with Chiara Galiffa (Cabinet of Commissioner Maroš Šefčovič)

7 Oct 2025 · US and EU trade relations in the context of the pharmaceutical sector

Meeting with Veronika Cifrová Ostrihoňová (Member of the European Parliament)

22 Sept 2025 · Current health situation in the EU

Meeting with Stine Bosse (Member of the European Parliament)

16 Sept 2025 · Clinical trials policy

AstraZeneca pushes for integrated cardio-renal-metabolic approach in EU plan

12 Sept 2025
Topic — The European Commission is developing a comprehensive plan to improve cardiovascular health outcomes.
Message — AstraZeneca requests an integrated approach to heart, kidney, and metabolic diseases. They propose mandatory, standardized health checks in primary care for adults and high-risk youth.12
Why — Standardised screening and protocols would increase the use of their medicines and diagnostic products.3
Impact — National health ministries could lose budget flexibility due to demands for ring-fenced funding.45
Read full response

Meeting with Rainer Becker (Director Health and Food Safety) and SANOFI

4 Sept 2025 · Exchange of views on multinational clinical trials in the context of the upcoming Biotech Act

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

2 Sept 2025 · Health policy

Meeting with Andreas Glück (Member of the European Parliament, Shadow rapporteur for opinion) and CSL Behring

15 Jul 2025 · CMA

Meeting with Jörgen Warborn (Member of the European Parliament)

14 Jul 2025 · Critical medicines

Meeting with Oliver Schenk (Member of the European Parliament, Rapporteur for opinion)

14 Jul 2025 · Critical Medicines Act

Meeting with Patricia Reilly (Cabinet of President Ursula von der Leyen)

14 Jul 2025 · Competitiveness of the biopharmaceutical sector

Meeting with Patricia Reilly (Cabinet of President Ursula von der Leyen)

14 Jul 2025 · to follow

Meeting with Mohammed Chahim (Member of the European Parliament, Shadow rapporteur for opinion) and European Federation of Pharmaceutical Industries and Associations and

25 Jun 2025 · Roundtable Critical Medicines Act

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

20 Jun 2025 · Competitividad del sector

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

13 Jun 2025 · Patient rights

AstraZeneca urges ambitious EU Biotech Act to boost competitiveness

11 Jun 2025
Topic — The Commission is consulting on measures to accelerate biotechnology innovation and market transition.
Message — AstraZeneca calls for an Act securing competitive IP and optimized clinical trial systems. They advocate for centralized diagnostic approvals and dedicated evidence frameworks for orphan drugs.12
Why — Centralization would reduce administrative burdens and provide greater certainty for AstraZeneca’s market entry timelines.34
Impact — National ethics committees lose independent oversight as approval processes are centralized and harmonized.5
Read full response

Meeting with András Tivadar Kulja (Member of the European Parliament)

24 Apr 2025 · PFAS

Meeting with András Tivadar Kulja (Member of the European Parliament)

24 Apr 2025 · Introductory meeting

Meeting with Vilija Sysaite (Cabinet of Executive Vice-President Stéphane Séjourné)

23 Apr 2025 · Trade, simplification, IP

AstraZeneca calls for stronger IP to revive EU competitiveness

17 Apr 2025
Topic — A consultation on a new EU strategy to boost innovation and competitiveness in life sciences.
Message — AstraZeneca demands a "sector omnibus package" to reduce "regulatory duplication" and financial burdens. They argue "innovation relies on robust IP protection" and oppose reducing regulatory data protections. The company seeks to "streamline and accelerate trials" by amending current clinical regulations.1234
Why — Stronger IP and fewer regulations would protect profits and lower operational compliance costs.56
Impact — Generic drug makers and environmental groups lose if patent shields expand and pollution rules ease.78
Read full response

Meeting with Laszlo Kristoffy (Cabinet of Commissioner Olivér Várhelyi)

28 Mar 2025 · Discussion about EU priorities in the area of public health.

Meeting with Ekaterina Zaharieva (Commissioner) and

24 Mar 2025 · Life Sciences Strategy

Meeting with Jessika Roswall (Commissioner) and

24 Mar 2025 · The climate-health nexus, Urban Wastewater Treatment Directive and PFAS restriction

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

21 Mar 2025 · Medicines

Meeting with Billy Kelleher (Member of the European Parliament)

5 Mar 2025 · Pharmaceutical strategy

Meeting with Andreas Glück (Member of the European Parliament)

4 Mar 2025 · Medcicines

Meeting with Kristian Vigenin (Member of the European Parliament)

6 Feb 2025 · Ongoing negotations on GPL

Meeting with Karin Karlsbro (Member of the European Parliament) and Läkemedelsindustriföreningen

29 Jan 2025 · Läkemedelsindustri

Meeting with Pascal Arimont (Member of the European Parliament)

28 Jan 2025 · Competitiveness of the pharmaceutical sector in Europe

Meeting with Stéphane Séjourné (Executive Vice-President) and

22 Jan 2025 · Economic state of Play of pharmaceutical sector

Meeting with Laurent Castillo (Member of the European Parliament)

10 Dec 2024 · Pharma

Meeting with Sander Smit (Member of the European Parliament)

22 Nov 2024 · ENVI

Meeting with Oliver Schenk (Member of the European Parliament)

21 Nov 2024 · Gesundheitspolitische Agenda in der EU - Prioritäten für die neue Legislaturperiode

Meeting with Brando Benifei (Member of the European Parliament)

21 Nov 2024 · Priorities for the new mandate on health

Meeting with Niels Flemming Hansen (Member of the European Parliament)

21 Nov 2024 · Priorities for the mandate

Meeting with Ingeborg Ter Laak (Member of the European Parliament)

21 Nov 2024 · Health policy, medicines

Meeting with Sakis Arnaoutoglou (Member of the European Parliament) and Novartis International AG

21 Nov 2024 · Pharma industry, innovations and environmental impacts

Meeting with Stefan Köhler (Member of the European Parliament) and Alexion Pharmaceuticals

21 Nov 2024 · Politischer Austausch

Meeting with Elena Nevado Del Campo (Member of the European Parliament)

20 Nov 2024 · Competitividad del sector farmaceútico

Meeting with Vytenis Povilas Andriukaitis (Member of the European Parliament) and European Cancer Organisation and

20 Nov 2024 · EU health policy

Meeting with Eero Heinäluoma (Member of the European Parliament)

20 Nov 2024 · Ajankohtaisaiheet

Meeting with Christophe Clergeau (Member of the European Parliament)

20 Nov 2024 · PFAS

Meeting with Marta Temido (Member of the European Parliament)

20 Nov 2024 · EU health priorities around prevention and immunization in Portugal

Meeting with Beatrice Timgren (Member of the European Parliament, Shadow rapporteur)

20 Nov 2024 · EU Chemical Policy

Meeting with Aura Salla (Member of the European Parliament)

20 Nov 2024 · The pharmaceutical regulation in the EU and the global competitiveness of pharmaceutical companies in the EU

Meeting with Tomislav Sokol (Member of the European Parliament) and Association of the European Self-Care Industry

14 Nov 2024 · Health policy

Meeting with Marta Temido (Member of the European Parliament)

14 Nov 2024 · EU health priorities around prevention and immunization

Meeting with Stine Bosse (Member of the European Parliament, Committee chair)

1 Oct 2024 · European health policy

Meeting with Nicolás González Casares (Member of the European Parliament)

1 Oct 2024 · Non-communicable diseases

Meeting with Cristian-Silviu Buşoi (Member of the European Parliament, Committee chair)

3 Apr 2024 · speaker at live debate -Future of health in the EU-

AstraZeneca urges greater developer involvement in EU health assessments

2 Apr 2024
Topic — The consultation concerns implementing rules for joint clinical assessments of new medicinal products.
Message — AstraZeneca requests to heighten the role of developers as key partners in evidence generation. They argue for sufficient time to produce a high-quality submission and comprehensive dossier.123
Why — This would allow the company to avoid duplicative processes and reduce work performed at risk.45
Read full response

Meeting with Anna Cavazzini (Member of the European Parliament, Committee chair) and Apple Inc. and

23 Feb 2024 · Aktuelle Themen in der Europapolitik und Sachsen

Meeting with Cristian-Silviu Buşoi (Member of the European Parliament)

15 Nov 2023 · speaker at Astra Zeneca Conference - Futureproofing EU healthcare systems to ensure timely innovatoon to patients

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

18 Sept 2023 · Medicines

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and Novartis International AG and

18 Jul 2023 · Directive on Medicinal products for human use

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and Affordable Medicines Europe and Pharma Deutschland e.V

6 Jul 2023 · Revision of Pharmaceutical Legislation (staff level)

Meeting with Heléne Fritzon (Member of the European Parliament)

29 Jun 2023 · Möte med Astra Zeneca

Meeting with Barry Andrews (Member of the European Parliament)

9 Jun 2023 · Pharmaceutical

Meeting with Elisabetta De Blasis (Member of the European Parliament, Shadow rapporteur)

31 May 2023 · Revision of the EU general pharmaceuticals legislation, EU Health data space

Meeting with Jessica Polfjärd (Member of the European Parliament)

27 Apr 2023 · Health policy

Meeting with Karin Karlsbro (Member of the European Parliament)

27 Apr 2023 · Pharma Package

Meeting with Barry Andrews (Member of the European Parliament)

27 Apr 2023 · EU Pharmaceutical Strategy

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

26 Apr 2023 · Medicines

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur) and Servier

28 Feb 2023 · Medicines

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

27 Jan 2023 · Medicines

Meeting with Andreas Glück (Member of the European Parliament, Committee chair)

6 Sept 2022 · COVID19 vaccine strategy

Meeting with Sara Cerdas (Member of the European Parliament)

5 Sept 2022 · Produção, Scale-Up e Policy em Vacinas

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

2 Sept 2022 · National Healthcare Systems Sustainability

Meeting with Stelios Kympouropoulos (Member of the European Parliament, Shadow rapporteur)

12 Jul 2022 · pMDIs

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

11 Jul 2022 · The current situation of the pandemic and the development and production of vaccines

AstraZeneca warns against rapid F-gas cuts for medical inhalers

29 Jun 2022
Topic — Review of EU rules regulating fluorinated greenhouse gases to align with climate goals.
Message — AstraZeneca requests maintaining current medical gas quotas until 2030 to protect patient safety. They also seek efficient regulatory pathways for approving new climate-friendly inhaler propellants.123
Why — A delayed phase-down prevents supply disruptions and provides time for necessary clinical trials.4
Impact — Respiratory patients risk losing access to effective treatments, potentially leading to poor health.5
Read full response

AstraZeneca urges clearer definitions for EU corporate sustainability rules

23 May 2022
Topic — The EU initiative establishes a framework for companies to address environmental and human rights impacts.
Message — AstraZeneca requests harmonised definitions for terms like 'value chains' and 'adverse impact' to ensure legal certainty. They also want reporting indicators to align with existing standards to reduce administrative burdens.12
Why — Harmonised rules would provide legal certainty and simplify data collection across the single market.3
Impact — Indirect suppliers in developing regions could lose market access due to data reporting challenges.4
Read full response

Meeting with Karin Karlsbro (Member of the European Parliament) and SANOFI and

17 May 2022 · Pharmaceuticals

Meeting with Susana Solís Pérez (Member of the European Parliament)

1 Apr 2022 · EU Pharmaceutical Strategy

Meeting with Cyrus Engerer (Member of the European Parliament)

6 Sept 2021 · Pharmaceutical Strategy

Response to Requirements for Artificial Intelligence

4 Aug 2021

AstraZeneca (AZ) welcomes the proposed draft Artificial Intelligence (AI) Act and believes that harmonised EU rules on AI can pre-empt a possible fragmentation of the single market and foster the safe and responsible development, use, and uptake of AI in the European Union. Tightening the definition of ‘AI’ and ‘Systems’ to exclude legacy activities: The language used to define AI in the draft legislation is very broad and includes all statistical computations and analyses. Like many of its peers in the biomedical, pharmaceutical, and healthcare sector, AZ is a science- and data-driven business. AZ has routinely used the scientific method, statistical analyses, and computational methods for decades. Applications include biological discovery science, the enabling of clinical trials, interventional research, drug product approval, and post-marketing activities. The currently proposed inclusive definition of AI would encompass a large portion of the daily work of many biomedical and pharmaceutical companies. These activities were historically neither thought of or classed as ‘AI’ nor identified as conferring additional risks (often to the contrary). We would appreciate further dialogue on a definition of AI that does not capture legacy activities and takes into consideration existing requirements in the field of diagnostics and medical products. Similarly, further guidance on the definition of a ‘system’ would be beneficial to data-driven industries to understand what activities are in and out of scope for this regulation. AZ’s AI applications: - AI systems put into service for own use: internal systems that include machine learning, language processing, and decision assistance and automation using AI. The developers of our AI solutions are often also the end-users - Upstream use cases, where sector-specific processes or regulations mitigate risk: include an AI modelling tool that predicts compound safety and efficacy prior to adding the compound to the company portfolio - Medical software products developed using or containing AI: use of AI and machine learning technologies to enhance the medical device development process and indeed as a core component of the medical device itself. We have developed quality management systems for medical device design, development, and manufacturing and have recently endeavoured to supplement these systems with good machine learning practices. - AI systems that support patient stratification e.g. diagnostics - Facial Recognition for employee and site security Determining AI risk categories: AZ supports the premise of the proposal that in the health sector where public health is paramount, AI supporting human decisions must be reliable and accurate. The proposal lays down a risk methodology to define “high-risk” AI systems and the European Council has called for a clear determination of those AI applications that should be considered high-risk. AZ’s supports this approach to ensure legal certainty and facilitates innovation and continued investments in AI technologies. We also strongly encourage a proportionate application of all relevant requirements. Our reading of the proposed Article 6 in conjunction with Annex II and Annex III of the draft Artificial Intelligence Act suggests a limited amount of AZ’s current applications of AI would be categorised as high-risk, including the following: - Software as a medical device; - AI systems acting as or supporting diagnostics (e.g. that support patient stratification); and - AI systems used in facial recognition for employee and site, and information security. Codes of Conduct: AZ develops and uses AI technology in line with its Principles for Ethical Data and AI as well as its Code of Ethics and Ethics & Transparency Commitment under its Sustainability Ambition. AZ is committed to review its Principles against relevant requirements incorporated in the final AI Act.
Read full response

Meeting with Pascal Canfin (Member of the European Parliament, Committee chair)

14 Apr 2021 · Covid 19

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

12 Apr 2021 · Vaccine production and delivery schedule for Q2 2021

Meeting with Thierry Breton (Commissioner)

11 Apr 2021 · Vaccine production and deliveries

Meeting with Pascal Canfin (Member of the European Parliament, Committee chair)

17 Mar 2021 · Covid 19

Meeting with Pascal Canfin (Member of the European Parliament)

24 Feb 2021 · Covid 19

Meeting with Sandra Gallina (Director-General Health and Food Safety)

11 Feb 2021 · vaccines - delivery schedule

Meeting with Sandra Gallina (Director-General Health and Food Safety)

1 Feb 2021 · vaccines

Meeting with Ursula von der Leyen (President) and SANOFI and

31 Jan 2021 · Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements

Meeting with Sandra Gallina (Director-General Health and Food Safety)

21 Jan 2021 · follow up vaccines

Meeting with Sandra Gallina (Director-General Health and Food Safety)

11 Jan 2021 · Follow-up over vaccines

AstraZeneca urges maintaining medical exemption for F-gas regulation

7 Sept 2020
Topic — The consultation reviews EU rules on fluorinated greenhouse gases to improve climate action.
Message — AstraZeneca requests maintaining the medical exemption until at least 2030 for product development. They want doctors to retain freedom to choose the best devices for patient needs. Strict safety requirements prevent the company from meeting a more ambitious development timeline.123
Why — This would provide the company time to complete regulatory approval for new inhaler devices.4
Read full response

AstraZeneca calls for strong IP and regulatory modernization

6 Jul 2020
Topic — EU consultation on a strategy for affordable medicines and pharmaceutical industry innovation.
Message — AstraZeneca calls for a stringent IP framework to attract investment and modernized regulatory systems. They suggest updating pricing for novel treatments and establishing a stakeholder forum on access.123
Why — Stronger IP and faster approvals would protect investments and increase market returns.45
Impact — Environmental goals may be sidelined as patient outcomes are prioritized in therapy choices.6
Read full response